TG Therapeutics Inc (NASDAQ:TGTX)
| 17.34 Delayed Data As of Feb 03 |  -0.63 / -3.51%Today’s Change | 3.48 Today|||52-Week Range 18.31 | +46.58% Year-to-Date |
Latest TGTX News | Press Releases
| TG Therapeutics (TGTX) Stock Moves -0.89%: What You Should Know Jan 30 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 17.97 |
| Today’s open | 17.50 |
| Day’s range | 17.11 - 18.31 |
| Volume | 289,339 |
| Average volume (3 months) | 4,503,226 |
| Market cap | $2.5B |
Data as of 4:00pm ET, 02/03/2023
Growth & Valuation
| Earnings growth (last year) | -8.68% |
| Earnings growth (this year) | +49.35% |
| Earnings growth (next 5 years) | -57.11% |
| Revenue growth (last year) | +4,300.66% |
| P/E ratio | NM |
| Price/Sales | 375.58 |
| Price/Book | 10.49 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| GRFSGrifols SA | +0.01 | +0.05% |
| XENEXenon Pharmaceutical... | 0.00 | 0.00% |
| CORTCorcept Therapeutics... | -0.15 | -0.61% |
| SAGESAGE Therapeutics In... | 0.00 | 0.00% |
Data as of 4:00pm ET, 02/03/2023
Financials
| Next reporting date | March 9, 2023 |
| EPS forecast (this quarter) | -$0.27 |
| Annual revenue (last year) | $6.7M |
| Annual profit (last year) | -$348.1M |
| Net profit margin | -5,204.08% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New York, New York |
Forecasts
